Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure

Heart Failure Clinical Trial

— GREARTWAL  

Official title:

Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04062500
• Other study ID #: GREARTWAL
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: December 31, 2027

Study information

• Verified date: August 2020
• Source: Shanghai 10th People's Hospital
• Contact: Dachun Xu, PhD
• Phone: 18917684045
• Email: xdc77[@]tongji.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this registry is to compile a large clinical database on the medical management of patients hospitalized with acute heart failure, using information collected from hospitals across China.

Description:

Registry for Longitudinal mortality and therapy in patients with Heart Failure is a large, multicenter, prospective, open-label registry of the management of patients treated in the hospital for acute heart failure in China. The objective of this study is to investigate the clinical features and prognosis of patients with heart failure, and discover the characteristics of high-risk heart failure patients, and elucidate critical factors which predict the development and outcomes of symptomatic heart failure patients.

1. To elucidate the clinical characteristics and prognostic risks of patients with heart failure.

2. To study the characteristics of high-risk heart failure patients and predict the key factors for the development of symptomatic heart failure patients.

3. To elucidate the compliance of patients with heart failure and the incidence of adverse drug effects.

4. To investigate the effect of self-management on outcomes in patients with heart failure.

5. To elucidate critical factors associated with the development and outcomes of heart failure.

6. To investigate hospitalization expenses for heart failure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10500
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2020
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• 1. 18 years and older. 2. Meet the diagnostic criteria of China 2018 or JACC/AHA 2017 or ESC 2016 heart failure guidelines.

3. Agree to be tested and sign an informed consent certificate.

Exclusion Criteria:

• 1. Age<18 years old. 2. Patients who refused to participate. 3. Patients may have a life expectancy of less than 1 years due to non- heart failure clinical conditions.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Other:
• Mortality and Rehospitalization rate
Mortality and Re-hospitalization of acute decompensated heart failure

Locations

Country	Name	City	State
China	Shanghai Tenth People's Hospital, Tongji University	Shanghai	Shanghai

Sponsors (11)

Lead Sponsor

Collaborator

Shanghai 10th People's Hospital

Beijing Chao Yang Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Hospital of China Medical University, Nanfang Hospital of Southern Medical University, Ningbo Medical Center Lihuili Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Shaanxi University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Xuhui Central Hospital, Shanghai, Yangpu District Central Hospital Affiliated to Tongji University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality of acute decompensated heart failure	In-hospital and Annual mortality	10 years
Primary	Re-hospitalization rate	Re-hospitalization of acute decompensated heart failure	10 years